Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-023604
Filing Date
2020-05-08
Accepted
2020-05-08 16:37:00
Documents
68
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q eidx-10q_20200331.htm   iXBRL 10-Q 1966463
2 EX-31 eidx-ex31_10.htm EX-31 18425
3 EX-32 eidx-ex32_12.htm EX-32 9961
  Complete submission text file 0001564590-20-023604.txt   7422516

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA eidx-20200331.xsd EX-101.SCH 55402
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE eidx-20200331_cal.xml EX-101.CAL 41048
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE eidx-20200331_def.xml EX-101.DEF 191179
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE eidx-20200331_lab.xml EX-101.LAB 422872
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eidx-20200331_pre.xml EX-101.PRE 327061
50 EXTRACTED XBRL INSTANCE DOCUMENT eidx-10q_20200331_htm.xml XML 1390585
Mailing Address 101 MONTGOMERY STREET, SUITE 2550 SAN FRANCISCO CA 94104
Business Address 101 MONTGOMERY STREET, SUITE 2550 SAN FRANCISCO CA 94104 650-391-9740
Eidos Therapeutics, Inc. (Filer) CIK: 0001731831 (see all company filings)

EIN.: 463733671 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38533 | Film No.: 20861164
SIC: 2834 Pharmaceutical Preparations